The development of platinum compounds and their possible combination.
Cisplatin plays a central role in cancer chemotherapy in spite of its toxicity. To circumvent this toxicity and to enhance its therapeutic index a lot of preclinical and clinical studies have been conducted and several thousand analogues have been synthesized. Much more analysis remains to be done, but nowadays, the absence of any definitive, biologically interpretable molecular predictor of activity is consistent with the idea that platinum compounds have multiple intracellular targets and that cells can have multiple mechanisms of resistance. This review analyses a part of these platinum compounds analyzed to date, their mechanism of action, resistance and the future trends in this sector.
Pasetto
Lara Maria
LM
Medical Oncology Division, Azienda Ospedale-Università, Via Gattamelata 64, 35128 Padova, Italy. laramary@libero.it
D'Andrea
Mario Rosario
MR
Brandes
Alba Ariela
AA
Rossi
Elena
E
Monfardini
Silvio
S
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008954:Models, Biological; D017671:Platinum Compounds / Q000138:chemical synthesis*
D000970:Antineoplastic Agents; D017671:Platinum Compounds